Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849667 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
A Phase 3 study, sponsored by Morphotek.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
NCT00849667: Clinical Trial Phase 3 study, sponsored by Morphotek.
NCT00849667 is a Phase 3 study that was terminated before completion, run by Morphotek. The registered enrollment target is 1,100 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00849667, a Phase 3 study, was terminated before completion, sponsored by Morphotek.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
Study Summary
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
Primary Outcome
PFS was defined as the time (in months) from the date of randomization to the date of the first observation of progression based on the independent radiologic assessment (modified response evaluation criteria in solid tumors \[RECIST\]), or date of death, whatever the cause. As per RECIST, disease progression was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. If progression or death was
Interventions
- DRUG Carboplatin
- DRUG Taxane
- DRUG Farletuzumab
- DRUG Farletuzumab-matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2009-04-16 |
| Est. Completion | 2013-04-12 |
| Phase | Phase 3 |
Why NCT00849667 stopped before completion
NCT00849667 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00849667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00849667 about?
NCT00849667 is a clinical study titled "Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse". This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
What is the current status of trial NCT00849667?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2009-04-16. Estimated completion is 2013-04-12.
What interventions are being tested in trial NCT00849667?
The interventions under investigation include: Carboplatin (DRUG), Taxane (DRUG), Farletuzumab (DRUG), Farletuzumab-matched placebo (DRUG).
Who is sponsoring clinical trial NCT00849667?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00849667's enrollment target sits among peer trials
1,100 252nd of 2000 higher than 1,736 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI